Literature DB >> 11108660

Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer.

I Bièche1, R Lidereau.   

Abstract

Loss of heterozygosity (LOH) on the long arm of chromosome 13 is common in human breast tumors, pointing to the existence of several suppressor genes in this region. LOH at 13q14 has been implicated in alterations of retinoblastoma gene (RB1) expression. However, attempts to identify a link between the absence of retinoblastoma protein expression and LOH at the RB1 locus by means of immunohistochemical techniques have produced conflicting results. Therefore, we quantified RB1 mRNA by means of reverse transcriptase-polymerase chain reaction in a large series of human sporadic primary breast tumors. RB1 gene underexpression was observed in 28 (21.7%) of 129 breast-tumor RNAs. Allelic loss at this locus correlated with RB1 mRNA underexpression (P < 10(-7)), demonstrating a causal link. These data, based on a technique other than immunohistochemistry, confirm that RB1 is the main target of the 13q14 LOH observed in human breast cancer. We also found that RB1 underexpression correlated with Scarff-Bloom-Richardson (SBR) histopathologic grade III (P = 0.033), negative estrogen-receptor status (P = 0.026) and large tumor size (P = 0.010). The latter correlation was due mainly to a high mitotic index (one of the three components comprising SBR grade), suggesting that RB1 influences the proliferation rate of breast tumors. RB1 status (underexpression vs. normal expression) was not associated with subsequent relapse or with shorter relapse-free survival. This study shows a major role of the RB1 gene in the pathogenesis of breast cancer. RB1 gene underexpression promotes breast-tumor aggressiveness and rapid tumor-cell proliferation, making RB1 an outstanding target for future gene-based breast-cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11108660

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  12 in total

1.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.

Authors:  Kimberly J Bussey; Koei Chin; Samir Lababidi; Mark Reimers; William C Reinhold; Wen-Lin Kuo; Fuad Gwadry; Hosein Kouros-Mehr; Jane Fridlyand; Ajay Jain; Colin Collins; Satoshi Nishizuka; Giovanni Tonon; Anna Roschke; Kristen Gehlhaus; Ilan Kirsch; Dominic A Scudiero; Joe W Gray; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

Review 2.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

3.  The molecular genetics of breast cancer and targeted therapy.

Authors:  Rachel Suter; James A Marcum
Journal:  Biologics       Date:  2007-09

4.  Molecular changes in primary breast tumors and the Nottingham Histologic Score.

Authors:  Rachel E Ellsworth; Jeffrey A Hooke; Brad Love; Darrell L Ellsworth; Craig D Shriver
Journal:  Pathol Oncol Res       Date:  2009-02-05       Impact factor: 3.201

5.  Alterations of the retinoblastoma gene in metastatic breast cancer.

Authors:  Elisabet Ognedal Berge; Stian Knappskog; Johan Richard Lillehaug; Per Eystein Lønning
Journal:  Clin Exp Metastasis       Date:  2011-01-21       Impact factor: 5.150

6.  SKY analysis revealed recurrent numerical and structural chromosome changes in BDII rat endometrial carcinomas.

Authors:  Eva Falck; Carola Hedberg; Karin Klinga-Levan; Afrouz Behboudi
Journal:  Cancer Cell Int       Date:  2011-06-27       Impact factor: 5.722

7.  Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays.

Authors:  I Bièche; M Olivi; C Noguès; M Vidaud; R Lidereau
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

8.  Prognostic value of CtIP/RBBP8 expression in breast cancer.

Authors:  Isabel Soria-Bretones; Carmen Sáez; Manuel Ruíz-Borrego; Miguel A Japón; Pablo Huertas
Journal:  Cancer Med       Date:  2013-10-03       Impact factor: 4.452

9.  The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.

Authors:  Jason I Herschkowitz; Xiaping He; Cheng Fan; Charles M Perou
Journal:  Breast Cancer Res       Date:  2008-09-09       Impact factor: 6.466

10.  Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution.

Authors:  Prashant Kumar; Malini Mukherjee; Jacob P S Johnson; Milan Patel; Bing Huey; Donna G Albertson; Karl Simin
Journal:  PLoS Genet       Date:  2012-11-15       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.